KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Account Payables (2017 - 2019)

Alnylam Pharmaceuticals (ALNY) has disclosed Change in Account Payables for 10 consecutive years, with -$30.1 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Change in Account Payables fell 431.18% year-over-year to -$30.1 million, compared with a TTM value of $12.4 million through Sep 2019, up 6.22%, and an annual FY2018 reading of $15.5 million, up 413.38% over the prior year.
  • Change in Account Payables was -$30.1 million for Q3 2019 at Alnylam Pharmaceuticals, down from $43.5 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $43.5 million in Q2 2019 and bottomed at -$30.1 million in Q3 2019.
  • Average Change in Account Payables over 4 years is $630833.3, with a median of $28500.0 recorded in 2015.
  • Peak annual rise in Change in Account Payables hit 6377.34% in 2019, while the deepest fall reached 431.18% in 2019.
  • Year by year, Change in Account Payables stood at $750000.0 in 2015, then soared by 1544.27% to $12.3 million in 2017, then surged by 30.78% to $16.1 million in 2018, then tumbled by 286.56% to -$30.1 million in 2019.
  • Business Quant data shows Change in Account Payables for ALNY at -$30.1 million in Q3 2019, $43.5 million in Q2 2019, and -$17.1 million in Q1 2019.